Prevention of Renal Interstitial Fibrosis by Suplatast in a Mouse Model

被引:0
|
作者
Honma, Shigeyoshi [1 ]
Komine, Kazuma [1 ]
Ota, Suzuka [1 ]
Toriyabe, Kohei [1 ]
Morita, Yuta [1 ]
Yoshida, Makoto [1 ]
机构
[1] Takasaki Univ Hlth & Welf, Fac Pharm, Dept Pharmacol, 60 Nakaorui Machi, Takasaki, Gunma 3700033, Japan
关键词
suplatast; fibrosis; extracellular signal-regulated kinase (ERK); janus kinase (JAK); signal transducer and activator of transcription (STAT); TOSILATE; INHIBITION; ACTIVATION; PROTECTS; KIDNEY; CELLS; TH1;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Suplatast is a T helper 2 (Th2) cytokine inhibitor. Here, we tested its therapeutic effects using a mouse model of renal interstitial fibrosis caused by unilateral ureteral obstruction ( UUO). In this model, suplatast was found to prevent the induced fibrosis in the obstructed kidney when given in the drinking water at 100 mg/kg/d. Mechanistically, suplaplast inhibited the phosphorylation of extracellular signal-regulated kinase (ERK) that was otherwise increased by UUO. Similarly, suplaplast reduced the increased accumulation of KIM-1, transforming growth factor beta (TGF-beta), type I collagen, interleukin-4 (IL- 4), janus kinase (JAK)1 and signal transducer and activator of transcription (STAT)3 mRNA seen in the kidneys of UUO-treated mice. Furthermore, STAT3 phosphorylation, which was stimulated by UUO, was also significantly decreased by suplatast. Collectively, these data show that suplatast reduces UUO-induced renal interstitial fibrosis via mechanisms including a reduction of phosphorylation of ERK and JAK/STAT pathway signaling.
引用
收藏
页码:61 / 66
页数:6
相关论文
共 50 条
  • [31] Molecular insights into renal interstitial fibrosis
    Eddy, AA
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (12): : 2495 - 2508
  • [32] Endothelial Dysfunction in Renal Interstitial Fibrosis
    Perry, Heather M.
    Okusa, Mark D.
    NEPHRON, 2016, 134 (03) : 167 - 171
  • [33] B lymphocytes in renal interstitial fibrosis
    Zhu, Fengge
    Bai, Xueyuan
    Chen, Xiangmei
    JOURNAL OF CELL COMMUNICATION AND SIGNALING, 2017, 11 (03) : 213 - 218
  • [34] Myofibroblast involvement in renal interstitial fibrosis
    Hewitson, T
    Becker, G
    NEPHROLOGY, 1996, 2 (04) : 229 - 234
  • [35] B lymphocytes in renal interstitial fibrosis
    Fengge Zhu
    Xueyuan Bai
    Xiangmei Chen
    Journal of Cell Communication and Signaling, 2017, 11 : 213 - 218
  • [36] Expression of Niban in renal interstitial fibrosis
    Liu, Jishi
    Qin, Jiao
    Mei, Wenjuan
    Zhang, Hao
    Yuan, Qiongjing
    Peng, Zhangzhe
    Luo, Renna
    Yuan, Xiangning
    Huang, Ling
    Tao, Lijian
    NEPHROLOGY, 2014, 19 (08) : 479 - 489
  • [37] Renal interstitial fibrosis: mechanisms and evaluation
    Farris, Alton B.
    Colvin, Robert B.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2012, 21 (03): : 289 - 300
  • [38] INTERSTITIAL MACROPHAGES AS MEDIATORS OF RENAL FIBROSIS
    EDDY, AA
    EXPERIMENTAL NEPHROLOGY, 1995, 3 (02): : 76 - 79
  • [39] THE PROGRESSION OF RENAL DISEASES - ON THE PATHOGENESIS OF RENAL INTERSTITIAL FIBROSIS
    MULLER, GA
    MARKOVICLIPKOVSKI, J
    RODEMANN, HP
    KLINISCHE WOCHENSCHRIFT, 1991, 69 (13): : 576 - 586
  • [40] The farnesoid X receptor agonist EDP-305 reduces interstitial renal fibrosis in a mouse model of unilateral ureteral obstruction
    Li, Shen
    Ghoshal, Sarani
    Sojoodi, Mozhdeh
    Arora, Gunisha
    Masia, Ricard
    Erstad, Derek J.
    Ferriera, Diego S.
    Li, Yang
    Wang, Guogiang
    Lanuti, Michael
    Caravan, Peter
    Or, Yat Sun
    Jiang, Li-Juan
    Tanabe, Kenneth K.
    Fuchs, Bryan C.
    FASEB JOURNAL, 2019, 33 (06): : 7103 - 7112